From: Impact of angina frequency on health utility values of patients with chronic stable angina
Characteristics | Placebo + Amlodipine (n = 283) | Ranolazine + Amlodipine (n = 281) |
---|---|---|
Age (years), mean ± SD | 61.3 ± 9.0 | 62.0 ± 8.7 |
Gender (M/W),% | 73/27 | 72/28 |
Race,% | ||
White | 99 | 98 |
Black | 1 | 1 |
Asian | 0 | <1 |
Geographic region,% | ||
Eastern Europe | 97 | 97 |
North America | 3 | 3 |
Concomitant use of LANs,% | 43 | 46 |
Weekly rate of angina attacks,trimmed mean ± SE | 5.68 ± 0.26 (n = 281) | 5.59 ± 0.21 (n = 277) |
Weekly rate of NTG consumption, trimmed mean ± SE | 5.02 ± 0.33 (n = 281) | 4.43 ± 0.26 (n = 277) |
SAQ score, mean ± SD | ||
Angina frequency | 40.0 ± 14.9 (n = 281) | 40.6 ± 13.2 (n = 277) |
Physical limitation | 48.9 ± 17.3 (n = 276) | 49.2 ± 17.4 (n = 271) |
Anginal stability | 57.2 ± 17.7 (n = 281) | 54.7 ± 18.0 (n = 277) |
Disease perception | 41.5 ± 17.8 (n = 281) | 41.6 ± 17.2 (n = 277) |
Treatment satisfaction | 75.4 ± 14.0 (n = 281) | 74.6 ± 14.3 (n = 277) |
History of unstable angina,% | 98 (35) | 100 (36) |
History of CHF,% | 145 (51) | 146 (52) |
NYHA functional class I | 38 (13) | 32 (11) |
NYHA functional class II | 86 (30) | 99 (35) |
NYHA functional class III | 21 (7) | 15 (5) |
NYHA functional class IV | 0 | 0 |
Diabetes mellitus,% | 54 (19) | 52 (19) |
Insulin-dependent | 2 (1) | 11 (4) |
Previous myocardial infarction,% | 233 (82) | 218 (78) |
Previous CABG,% | 34 (12) | 28 (10) |
Previous PCI | 25 (9) | 34 (12) |
Intermittent claudication,% | 32 (11) | 39 (14) |
Hypertension,% | 257 (91) | 246 (88) |